Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | HPGD | P15428 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202697 | 0.79 | SRC (0.40) | NPC1RAB9AMEN1KMT2ACYP3A4 | |
| SCHEMBL241448 | 0.79 | MPO (0.40) | NPC1RAB9AMPOALDH1A1HPGD | |
| SCHEMBL13163265 | 0.79 | ALDH1A1 (0.41) | NPC1RAB9AMEN1KMT2AMPO | |
| SCHEMBL13163266 | 0.77 | SMN1; SMN2 (0.43) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL13993590 | 0.77 | ALDH1A1 (0.38) | NPC1RAB9AMEN1KMT2AMPO | |
| SCHEMBL13163262 | 0.76 | SMN1; SMN2 (0.40) | NPC1RAB9AMEN1KMT2AMPO | |
| SCHEMBL12861068 | 0.75 | ALDH1A1 (0.44) | NPC1RAB9AMEN1KMT2ACYP3A4 | |
| SCHEMBL12861090 | 0.74 | SRC (0.32) | — | |
| SCHEMBL4989870 | 0.71 | CYP3A4 (0.41) | NPC1RAB9AMEN1KMT2ACYP3A4 | |
| SCHEMBL12559480 | 0.70 | MEN1 (0.39) | NPC1RAB9AMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389721-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389721-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389721-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2012015875-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015901-A1 | METHODS FOR TREATING GASTRIC AND PANCREATIC MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015901-A1 | METHODS FOR TREATING GASTRIC AND PANCREATIC MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120004235-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004235-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004235-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-06-09 | — | — | US | disclosed |
| US-20080090831-A1 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-04-17 | — | — | US | disclosed |
| US-20080090831-A1 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-04-17 | — | — | US | disclosed |
| US-7319105-B2 | Methylenedioxy-fused heterocycles, especially 8,10-dioxa-4,5,6,12-tetraaza-cyclopenta[b]chrysen-13-ones; 8,10-dioxa-1,4,5,6,12-pentaaza-cyclopenta[b]chrysen-13-ones; 8,10,12-trioxa-5,6-diaza-cyclopenta[b]chrysenes; and 8,10,12-trioxa-6-aza-cyclopenta[b]chrysenes; topoisomerase inhibitors; treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319105-B2 | Methylenedioxy-fused heterocycles, especially 8,10-dioxa-4,5,6,12-tetraaza-cyclopenta[b]chrysen-13-ones; 8,10-dioxa-1,4,5,6,12-pentaaza-cyclopenta[b]chrysen-13-ones; 8,10,12-trioxa-5,6-diaza-cyclopenta[b]chrysenes; and 8,10,12-trioxa-6-aza-cyclopenta[b]chrysenes; topoisomerase inhibitors; treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-01-15 | — | — | US | disclosed |
| US-7049315-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060052381-A1 | Solubilized topoisomerase poisons | LAVOIE EDMOND J | 2006-03-09 | — | — | US | disclosed |
| EP-1465625-A4 | SOLUBILIZED TOPOISOMERASE POISONS | UNIV RUTGERS (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050009824-A1 | Solubilized topoisomerase poisons | RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE | 2005-01-13 | — | — | US | disclosed |
| EP-1465625-A2 | SOLUBILIZED TOPOISOMERASE POISONS | Rutgers, The State University (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003041660-A2 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009824-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | NPC1 2748/4885RAB9A 3163/4885MEN1 2154/4885 |
| US-20120004235-A1 | METHODS TO TREAT CANCER | TP53, CCNY, ABCB1 | NPC1 234/4885RAB9A 998/4885MEN1 288/4885 |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | NPC1 2748/4885RAB9A 3163/4885MEN1 2154/4885 |
| US-20060052381-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | NPC1 2748/4885RAB9A 3163/4885MEN1 2154/4885 |
| US-20080090831-A1 | CYTOTOXIC AGENTS | TOP1, TOP2A, TOP2B | NPC1 715/4885RAB9A 3543/4885MEN1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.